Skip to main content

Kenvue company profile

  • KVUE · NYSE
  • Consumer goods
  • Personal Care Products
  • S&P 500
$19.31Close 30 Oct 2026

About Kenvue

Kenvue Inc. is a consumer health company that develops, markets, and sells over-the-counter medicines, skin health and beauty products, and essential health products. Its portfolio is organized into three reportable segments: Self Care, Skin Health and Beauty, and Essential Health. Major brands include Tylenol, Listerine, Neutrogena, Aveeno, BAND-AID Brand, Johnson's, and Zyrtec. Products are sold to consumers through retail and online channels, and are marketed in more than 165 countries across North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. About 60% of fiscal 2025 sales volume came from in-house manufacturing facilities, with the remainder supplied by external third-party manufacturers. The company employed approximately 22,000 people as of December 28, 2025.

A summary of the business section of the company's latest annual report, filed 20 Feb 2026.

Company facts

TickerKVUE · NYSE
SectorConsumer goods
IndustryPersonal Care Products
IndexS&P 500
Fiscal year ends28 December
Reporting currencyUSD
CIK1944048
Latest annual report10-K, filed 20 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Jeffrey C. SmithDirector27.3M · 1.42%Disposition to the issuer, 2 Nov 2026
Thibaut MongonChief Executive Officer · Director2.8M · < 1%Shares withheld for tax, 5 Mar 2025
Carlton LawsonGroup President EMEA &amp; LA615K · < 1%Disposition to the issuer, 2 Nov 2026
Meredith (Meri) StevensChief Operations Officer575K · < 1%Disposition to the issuer, 2 Nov 2026
Matthew OrlandoGeneral Counsel511K · < 1%Disposition to the issuer, 2 Nov 2026
Paul RuhChief Financial Officer322K · < 1%Option exercise, 5 Mar 2025
Kirk L. PerryChief Executive Officer · Director76.9K · < 1%Disposition to the issuer, 2 Nov 2026
Richard E. Allison, Jr.Director61.9K · < 1%Disposition to the issuer, 2 Nov 2026
Michael E. SneedDirector37.1K · < 1%Disposition to the issuer, 2 Nov 2026
Melanie L. HealeyDirector26.5K · < 1%Disposition to the issuer, 2 Nov 2026
Michael WondraschChief Tech &amp; Data Officer0 · < 1%Disposition to the issuer, 2 Nov 2026
Tillett CarolineChief Scientific Officer—Disposition to the issuer, 2 Nov 2026
Howlett HeatherInterim CFO &amp; CAO—Disposition to the issuer, 2 Nov 2026
Dyer RussellChief Corp. Affairs Officer—Disposition to the issuer, 2 Nov 2026
Dasgupta AnindyaGroup President, Asia Pacific—Disposition to the issuer, 2 Nov 2026
Curado Gomes de Lemos LeonardoGroup President, Latin America—Disposition to the issuer, 2 Nov 2026
Alvarado LuaniChief People Officer—Shares withheld for tax, 10 Mar 2026
Meurer JanGroup President, North America—Option exercise, 5 Mar 2025
Tavares BernardoChief Tech & Data Officer—Option exercise, 5 Mar 2025
Xie BingGroup President APAC—Shares withheld for tax, 5 Mar 2025

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

KVUE in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.